-5%
Brezofil is indicated for the management of:
- Bronchial asthma
- Bronchospasm
- Chronic obstructive pulmonary disease (COPD)
- Pulmonary disorders associated with bronchial spasm
Doxophylline is a newer-generation bronchodilator that differs structurally from theophylline due to the presence of a dioxolane group at position 7. This structural modification allows doxophylline to selectively inhibit phosphodiesterase-4 (PDE-4), resulting in relaxation of bronchial smooth muscle and improved airflow.
Unlike theophylline, doxophylline has lower affinity for adenosine A1 and A2 receptors, which contributes to its improved safety profile and reduced cardiovascular side effects. Additionally, doxophylline inhibits platelet-activating factor (PAF) and suppresses leukotriene production, further supporting its anti-inflammatory and bronchodilatory effects.
Overdose may result in life-threatening cardiac arrhythmias and tonic-clonic seizures. There is no specific antidote. Management includes symptomatic and supportive treatment, particularly addressing cardiovascular complications. Treatment may be resumed at a reduced dose once all toxic symptoms have resolved, under medical supervision.